《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2011年 > 5期

甘精胰岛素用于2型糖尿病患者围手术期的

来自:中国糖尿病资讯网  编辑:huizi|点击数:|2011-10-20

作者单位:330006南昌,南昌大学第二附属医院内分泌科

通讯作者:赖晓阳,E-mail:laixyang60@sina.com

甘精胰岛素用于2型糖尿病患者围手术期的

疗效及安全性评价

熊燕赖晓阳张美英

【摘要】目的

观察2型糖尿病(T2DM)患者围手术期甘精胰岛素治疗的临床疗效及安全性。方法将60例拟行手术治疗的T2DM患者分为甘精胰岛素治疗组(Gla组,30例)及分次皮下注射胰岛素组(MDI组,30例),控制围手术期血糖。根据血糖监测结果调整药物剂量,比较2组患者降糖疗效及安全性。结果两组均可有效降低血糖(P<0.01),降糖效果无明显差异(P>0.05)。但Gla组血糖波动更小,达到良好血糖控制的所需时间明显缩短(P<0.01);Gla组胰岛素用量、低血糖发生率、切口感染或延迟愈合率均少于MDI组(P<0.05)。结论甘精胰岛素治疗能有效、安全、平稳、迅速地控制血糖,尤其适用于需要更有效补充基础胰岛素治疗阶段的糖尿病围手术期患者,值得临床推广运用。

【关键词】糖尿病,2型;围手术期;甘精胰岛素

doi:10.3969/j.issn.1006-6187.2011.05.005

Effecttivity and safety of glargine treatment on perioperative patients with type 2 diabetes

XIONG Yan, LAI Xiao-yang,ZHANG Mei-ying. Department of Endocrinology, The Second Affiliated Hospital of Nanchang University,Nanchang 330006,China

Corresponding author: LAI Xiao-yang,E-mail:laixyang60@sina.com

【Abstract】ObjectiveTo observe the clinical effectivity and safety of Glargine treatment in perioperative patient with type 2 diabetes.Methods60 T2DM patients scheduled for surgery were divided into glargine insulin group (Gla, n=30) and MDI group (Humulin N, n=30). The Dosage was adjusted according to a blood glucose fluctuations to compare the effect and safety between the two groups.ResultsThe levels of blood glucose in the two groups were reduced after treatments (P<0.01) and there is no significant difference in hypoglycemic effect between the two groups (P>0.05). But the blood glucose fluctuation was smaller in Gla group than in MDI group and the glucose target arrival time was shorter in Gla group than in MDI group (P<0.01). The insulin dosage, the incidences of hypoglycemia and wound infection and delayed healing rate were less in Gla group than in MDI group (P<0.05).ConclusionsGlargine treatment can effectively, rapidly and savely control the blood glucose and is especially suitable for the perioperative patient requiring a sufficient basal insulin.

【Key words】Diabetes mellitus, type 2; Perioperative period; Insulin glargine

上一篇:解偶联蛋白2基因多态性与糖尿病 下一篇:新诊断的2型糖尿病患者胰岛素强化治疗前后